Ligand Pharmaceuticals 1 article

Rather than being defined by a laboratory platform, Ligand Pharmaceuticals is a biopharmaceutical royalty and platform-technology company associated with royalty biotechnology model. The company links capital and asset ownership through modified cyclodextrin excipient platform and drug formulation enabling technology; NITRICIL nitric oxide technology supplies additional context for the medicines or technologies behind the royalty streams. GenoMethods separates royalty ownership from the underlying medicines and developers; the business model of Ligand Pharmaceuticals also includes formulation technology partnerships.